The potential for NSAIDs to adversely affect the occurrence or severity of COVID-19 via upregulated expression of ACE-2 has been disputed, with several studies reporting that previous and concurrent use of ACE inhibitors or angiotensin receptor blockers, which are widely known to cause upregulated expression of ACE-2, has no impact on COVID-19 frequency or severity24–27. The gene discussed is ACE; the disease is COVID-19.